Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals, Inc. | 2026-05-22 14:59:46 | 13.57 | -0.35 | -2.51 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMLX | 0001658551 | Amylyx Pharmaceuticals, Inc. | US03237H1014 | — | 464600503 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 55 CAMBRIDGE PARKWAY | CAMBRIDGE | MA | 02142 | UNITED STATES | US | 617-682-0917 | 55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA, 02142 | 55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA, 02142 | — | — | 2013 | — | — | https://www.amylyx.com/ | 518,200,000 | 111,026,477 | 111,186,317 | Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. | 2026-05-21 17:04:42 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 518,200,000 | -117,081,800,000 | -99.5594 | 110,536,944 | 21,934,476 | 24.7561 |
| 2024 | 117,600,000,000 | 116,290,000,000 | 8,877.0992 | 88,602,468 | 20,820,329 | 30.7165 |
| 2023 | 1,310,000,000 | 521,900,000 | 66.2226 | 67,782,139 | 1,065,751 | 1.5974 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Camille L. Bedrosian, M.D. | Chief Medical Officer | 2025 | 575,000 | 0 | 246,996 | 275,569 | 157,237 | 1,567,674 |
| Justin Klee | Director, Co-Chief Executive Officer | 2025 | 686,200 | 0 | 650,226 | 548,098 | 17,500 | 2,719,807 |
| James Frates | Chief Financial Officer | 2025 | 540,600 | 0 | 246,996 | 259,083 | 17,500 | 1,375,327 |
| Joshua Cohen | Director, Co-Chief Executive Officer | 2025 | 686,200 | 0 | 650,226 | 548,098 | 17,500 | 2,719,807 |
| Gina M. Mazzariello | Chief Legal Officer, General Counsel | 2024 | 478,400 | 0 | 805,798 | 219,844 | 17,250 | 2,298,996 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 136 |
| 2024 | 123 |
| 2023 | 384 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 0 | 87,371,000 | 380,786,000 |
| Cost Of Revenue | 0 | 5,953,000 | 25,441,000 |
| Gross Profit | 0 | 81,418,000 | 355,345,000 |
| Research And Development Expenses | 90,404,000 | 104,084,000 | 128,187,000 |
| General And Administrative Expenses | 62,887,000 | 114,331,000 | 188,356,000 |
| Operating Expenses | 153,291,000 | 402,102,000 | 341,984,000 |
| Operating Income | -153,291,000 | -314,731,000 | 38,802,000 |
| Net Income | -144,735,000 | -301,743,000 | 49,271,000 |
| Earnings Per Share Basic | -1.53 | -4.43 | 0.73 |
| Earnings Per Share Diluted | -1.53 | -4.43 | 0.7 |
| Weighted Average Shares Outstanding Basic | 94,565,567 | 68,142,158 | 67,234,465 |
| Weighted Average Shares Outstanding Diluted | 94,565,567 | 68,142,158 | 69,991,340 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 226,651,000 | 77,391,000 | 170,201,000 |
| Marketable Securities Current | 90,328,000 | 99,110,000 | 201,161,000 |
| Accounts Receivable | 88,000 | 447,000 | 40,050,000 |
| Inventories | — | 0 | 38,323,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 6,604,000 | 12,484,000 | 14,931,000 |
| Total Assets Current | 323,671,000 | 189,432,000 | 464,666,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 310,000 | 961,000 | 2,686,000 |
| Other Assets Non Current | — | 24,000 | 701,000 |
| Total Assets Non Current | 8,974,000 | 4,202,000 | 52,788,000 |
| Total Assets | 332,645,000 | 193,634,000 | 517,454,000 |
| Accounts Payable | 3,519,000 | 2,939,000 | 22,061,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 17,910,000 | 23,949,000 | 57,724,000 |
| Total Liabilities Current | 22,688,000 | 28,406,000 | 82,042,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 4,698,000 | 463,000 | 1,980,000 |
| Total Liabilities | 27,386,000 | 28,869,000 | 84,022,000 |
| Common Stock | 11,000 | 7,000 | 7,000 |
| Retained Earnings | -751,427,000 | -606,692,000 | -304,949,000 |
| Accumulated Other Comprehensive Income | 404,000 | -92,000 | 197,000 |
| Total Shareholders Equity | 305,259,000 | 164,765,000 | 433,432,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 525,000 | 904,000 | 1,088,000 |
| Share Based Compensation Expense | 27,645,000 | 33,038,000 | 37,161,000 |
| Other Non Cash Income Expense | 169,000 | — | — |
| Change In Accounts Receivable | -359,000 | -39,602,000 | 24,744,000 |
| Change In Inventories | — | 9,253,000 | 73,129,000 |
| Change In Non Trade Receivables | -24,000 | — | -23,000 |
| Change In Other Assets | -5,960,000 | -4,988,000 | 231,000 |
| Change In Accounts Payable | 580,000 | -19,102,000 | 15,882,000 |
| Change In Other Liabilities | -6,598,000 | -59,810,000 | — |
| Cash From Operating Activities | -123,343,000 | -167,647,000 | 11,919,000 |
| Purchases Of Marketable Securities | 231,823,000 | 231,986,000 | 300,826,000 |
| Sales Of Marketable Securities | 246,000,000 | 344,000,000 | 394,120,000 |
| Acquisition Of Property Plant And Equipment | 138,000 | 157,000 | 1,241,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 14,039,000 | 75,654,000 | 92,053,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 256,314,000 | 327,000 | 5,725,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 256,313,000 | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 257,029,000 | 348,000 | 3,543,000 |
| Change In Cash | 148,799,000 | -92,083,000 | 107,675,000 |
| Cash At End Of Period | 226,651,000 | 77,391,000 | 170,201,000 |
| Income Taxes Paid | -1,038,000 | 708,000 | 6,389,000 |
| Interest Paid | — | — | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.53 | -4.43 | 0.73 |
| Price To Earnings Ratio | -7.8954 | -0.8533 | 20.1644 |
| Earnings Growth Rate | -65.4628 | -706.8493 | -121.5339 |
| Price Earnings To Growth Ratio | 0.1206 | 0.0012 | -0.1659 |
| Book Value Per Share | 3.228 | 2.418 | 6.4466 |
| Price To Book Ratio | 3.7422 | 1.5633 | 2.2834 |
| Ebitda | -145,248,000 | -300,131,000 | 56,748,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | -126,000 | -821,000 | 1,163,000 |
| Free Cash Flow | -123,217,000 | -166,826,000 | 10,756,000 |
| Return On Equity | -0.4741 | -1.8314 | 0.1137 |
| One Year Beta | 1.0667 | 1.8471 | 1.2049 |
| Three Year Beta | 1.2634 | 1.1972 | 1.0703 |
| Five Year Beta | 1.1594 | 1.1972 | 1.0703 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Bedrosian Camille L | Chief Medical Officer | 2026-03-05 | 95,990 | A | 265,285 |
| Bedrosian Camille L | Chief Medical Officer | 2026-03-05 | 143,985 | A | 143,985 |
| Klee Justin B. | Director, Co-Chief Executive Officer | 2026-03-05 | 248,865 | A | 3,583,481 |
| Klee Justin B. | Director, Co-Chief Executive Officer | 2026-03-05 | 373,295 | A | 373,295 |
| FRATES JAMES M | Chief Financial Officer | 2026-03-05 | 95,990 | A | 261,628 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Christopher L. Jacobs | 2022-11-16 | NY27 | Purchase | 2022-10-12 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| STEMPOINT CAPITAL LP | 2026-03-31 | 9,308,622 | 669,685 | 13.9 |
| JANUS HENDERSON GROUP PLC | 2026-03-31 | 69,256,554 | 4,986,073 | 13.89 |
| ADAR1 Capital Management, LLC | 2026-03-31 | 13,908,396 | 1,000,604 | 13.9 |
| Amundi | 2026-03-31 | 179,241 | 12,895 | 13.9 |
| EverSource Wealth Advisors, LLC | 2026-03-31 | 361 | 26 | 13.8846 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| iSHARES TRUST | 2026-03-31 | iShares U.S. Pharmaceuticals ETF | IHE | 233,280 | 3,242,592 | 0.3241 |
| AQR Funds | 2026-03-31 | Class R6 | QSMRX | 15,222 | 211,585.8 | 0.1268 |
| AQR Funds | 2026-03-31 | Class N | ASMNX | 15,222 | 211,585.8 | 0.1268 |
| AQR Funds | 2026-03-31 | Class I | ASMOX | 15,222 | 211,585.8 | 0.1268 |
| Bridge Builder Trust | 2026-03-31 | Bridge Builder Small/Mid Cap Growth Fund | BBGSX | 209,936 | 2,918,110.4 | 0.0316 |